eg 626 has been researched along with vorinostat in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gou, S; Liu, Q; Wang, X; Wang, Y; Zhang, B | 1 |
1 other study(ies) available for eg 626 and vorinostat
| Article | Year |
|---|---|
Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
Topics: Acetylation; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Liver Neoplasms; Male; Mice; Molecular Docking Simulation; Phthalazines; Quinazolinones; Signal Transduction; Structure-Activity Relationship; Tubulin; Tumor Suppressor Protein p53; Vorinostat | 2022 |